Lundbeck continued on its solid transformation journey with another consensus-beating quarter. Q3 16 total revenue was up 8% yoy to DKK3.9bn (+6% in LC), primarily driven by five key products (all in LC) – Rexulti (+324%), Northera (+142%), Brintellix/Trintellix (+65%), Abilify Maintena (+51%) and Onfi (+37%). These were more than able to cushion the negative impact stemming from the generic erosion of Xenazine (-38%) and the loss of sales on Azilect (-73%) due to the returning of the E
10 Nov 2016
Another guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Another guidance upgrade
Lundbeck continued on its solid transformation journey with another consensus-beating quarter. Q3 16 total revenue was up 8% yoy to DKK3.9bn (+6% in LC), primarily driven by five key products (all in LC) – Rexulti (+324%), Northera (+142%), Brintellix/Trintellix (+65%), Abilify Maintena (+51%) and Onfi (+37%). These were more than able to cushion the negative impact stemming from the generic erosion of Xenazine (-38%) and the loss of sales on Azilect (-73%) due to the returning of the E